Michael Morse Named Director, Finance and Administration of
Peptimmune, Inc.
CAMBRIDGE, Mass., Jan. 22 /PRNewswire/ -- Peptimmune, Inc. today announced the appointment of Michael Morse,
C.P.A., as Director, Finance and Administration. Mr. Morse joins Peptimmune from Procept, Inc., a publicly traded
biopharmaceutical company, where he served as Controller and Director of Financial Reporting.
''Michael Morse brings to Peptimmune broad expertise in financial management and significant experience in biotechnology,''
said Ben Bronstein, President and CEO of Peptimmune. ''Michael is an important addition to the Company's management
team, and we look forward to his input as we build our core organization to further advance our novel technologies for
modulating the immune system.''
Previous to Procept Inc. [Nasdaq:PRCT - news], Mr. Morse held the position of General Accounting Manager at
Kidde-Fenwal, Inc. In addition, he has performed various financial management positions within manufacturing, marketing, and
U.S. sales operations at Wang Laboratories, Inc. Mr. Morse holds a B.S. in accounting, summa cum laude from Bentley
College, an M.B.A. from Boston University Graduate School of Management, and an M.S. in Taxation, with distinction from
Bentley College.
Peptimmune, Inc. discovers and develops therapeutics based on an advanced understanding of antigen processing and
presentation, the initiating events of immune response. The Company is advancing three technology platforms for selectively
modulating the immune system based on fundamental discoveries in the laboratories of its scientific founders, Jack Strominger,
M.D., Higgins Professor of Biochemistry at Harvard University and the Dana Farber Cancer Institute and Hidde Ploegh,
Ph.D., Edward Mallinckrodt Jr. Professor of Immunopathology at Harvard Medical School. The Company's initial disease
targets include multiple sclerosis, rheumatoid arthritis, pemphigus vulgaris and AIDS. |
